Shares of Lev Pharmaceuticals Inc. tumbled 33 percent after the FDA requested additional information - though likely no new trials - prior to an approval of Cinryze, the company's C1 inhibitor in hereditary angioedema. (BioWorld Today)

Shares of Lev Pharmaceuticals Inc. tumbled 33 percent after the FDA requested additional information - though likely no new trials - prior to an approval of Cinryze, the company's C1 inhibitor in hereditary angioedema. (BioWorld Today)